PerkinElmer

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With a global network and localized agility, the company serves a diverse range of organizations from pharmaceutical and biotech to clinical labs, academia, and governments. It is headquartered in Waltham, MA.

PerkinElmer (PKI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why PerkinElmer (PKI) Might be Well Poised for a Surge

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Wolfe Virtual Healthcare Conference on Thursday, November 19 at 11:25 a.m. ET. Prahlad Singh, president and chief executive officer of PerkinElmer, will provide an update of the Company and its strategic priorities. A live audio webcast of the presentation will be available on the Investors section of the Company's we

PerkinElmer to Present at Wolfe Virtual Healthcare Conference

PerkinElmer (PKI) possesses solid growth attributes, which could help it handily outperform the market.

Here is Why Growth Investors Should Buy PerkinElmer (PKI) Now

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 1:20 p.m. ET. Jamey Mock, SVP and chief financial officer of PerkinElmer, will provide an update on the Company and its strategic priorities. A live audio webcast of the presentation will also be available on the Investors section of the Company's w

PerkinElmer to Present at Stifel Virtual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million).

PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million)

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow sample pooling with PerkinElmer® New Coronavirus Nucleic Acid Detection Kit to increase the number of individuals who can be tested without increasing resources. This validation of batch testing using the industry's most sensitive assay to date according to the FDA Reference Panel leverages its proven ability to det

PerkinElmer COVID-19 Test Kit Receives FDA Emergency Use Authorization for Sample Pooling

PerkinElmer, Inc. (PKI) CEO Prahlad Singh on Q3 2020 Results - Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 4, 2020. The Company reported GAAP earnings per share from continuing operations of $1.57, as compared to GAAP earnings per share from continuing operations of $0.53 in the third quarter of 2019. GAAP revenue for the quarter was $964.0 million, as compared to $706.9 million in the third quarter of 2019

PerkinElmer Announces Financial Results for the Third Quarter of 2020

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Launches immunoassay to help in researcher's fight against neurodegenerative diseases such as Parkinson's and Alzheimer's.

PerkinElmer Launches Industry First No-Wash Immunoassay For Phospho Ubiquitin Ser65 to Help Drive Neuroscience Disease and Therapeutics Research Forward

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30 countries by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD). This test is currently under review by the U.S. FDA for Emergency Use Authorization (EUA). The multi-analyte panel enables labs to detect and differentiate between SARS-CoV-2, influen

PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-19

PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at Diagnostics segment.

PerkinElmer (PKI) to Post Q3 Earnings: What's in the Offing?

WALTHAM, Mass.--(BUSINESS WIRE)--Covid-19 News: The NIH's NCATS division is using PerkinElmer's AlphaLISA immunoassay to screen compounds for potential drug repurposing candidates.

PerkinElmer Immunoassay Helps NIH NCATS Team Identify Therapeutic Compounds Capable of Disrupting the SARS-CoV-2 Spike Protein/ACE2 Interaction

Arthur J. Gallagher & Co.

Stanley Black & Decker

Vertex Pharmaceuticals

Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J.

Bet on These 5 Top-Ranked Stocks With Strong Sales Growth

Does PerkinElmer (PKI) have what it takes to be a top stock pick for momentum investors? Let's find out.

PerkinElmer (PKI) Is Up 4.11% in One Week: What You Should Know

PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why PerkinElmer (PKI) is Poised to Beat Earnings Estimates Again

WALTHAM, Mass.--(BUSINESS WIRE)--The table in the release was incorrect. The corrected table should read: PerkinElmer, Inc: PerkinElmer, Inc. and SubsidiariesRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)     PKI Three Months Ended October 4, 2020 Organic revenue growth: Reported revenue growth 35% Less: effect of foreign exchange rates 1% Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses 1% Organic revenue growth 33% (1) amounts

CORRECTING and REPLACING PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 35% and 33%, respectively, for the third quarter ended October 4, 2020. The strong revenue growth performance was driven by continued better-than-expected demand for PerkinElmer’s full-suite of solutions aimed at helping support customers’ COVID-19 testing needs across the globe. De

PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that the first Turnkey Lighthouse lab in Newport, South Wales, is now processing COVID-19 testing samples as part of the Company’s collaboration with the Department of Health and Social Care (DHSC) in support of the UK Government’s Test and Trace strategy. The Newport lab is the first facility to be brought online by PerkinElmer with the DHSC. DHSC and PerkinElmer a

Newport, Wales Laboratory Goes Live as First Lighthouse Lab featuring PerkinElmer’s COVID-19 Solutions

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer launches industry first fully-automated sample prep and analysis workflow for pesticide residue testing of cannabis and hemp flowers.

PerkinElmer Launches Industry First, Fully Automated Workflow for Cannabis & Hemp Pesticide Residue Testing

Becton, Dickinson and Co.

Fluidigm

Hologic

Eli Lilly

Luminex

QuidelOrtho Corp

QIAGEN

You know what they say! To the most sensitive tests go the spoils.

The FDA Just Ranked Coronavirus Tests by Sensitivity. Here's What That Means

WALTHAM, Mass.--(BUSINESS WIRE)--SOC 2 Attestation of PerkinElmer Informatics solutions gives biopharmas added peace of mind for drug data security and availability in the cloud

PerkinElmer Signals Notebook and PerkinElmer Signals Medical Review Cloud-Based Software Gain SOC 2 Attestation for Biopharmaceutical Research and Clinical Trial Data

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that the Company’s EONIS™ screening assay for newborns that simultaneously tests for SMA (spinal muscular atrophy), SCID (severe combined immunodeficiency) and XLA (X-linked agammaglobulinemia) has received CE-IVD approval. This IVD RT-PCR assay integrates into PerkinElmer’s entire newborn screening workflow to provide labs with a complete, single source solution en

PerkinElmer EONIS Screening Test Receives CE-IVD Clearance

Activision Blizzard

Lennar

Thor Industries

Vectrus

There has been a small bounce in the morning session as stocks try to rebound off their lows for the week. However, this marks the longest weekly downturn of the market since August 2019.

Top Stocks To Buy Today As Rocky September Leads To Loss Records

PerkinElmer Inc. (PKI) tops the list of molecular diagnostic tests for Covid-19 based on its ability to detect the smallest amount of virus, according to a report from the Food and Drug Administration.

PerkinElmer Covid-19 Test Heads FDA List for Superior Detection

KLA-Tencor

Timken

TransUnion

Solid sales growth is a major characteristic of potential winners. The firms that put more emphasis on sales management have a competitive advantage, as strong sales usually get converted into growth.

News for PerkinElmer Stock (PKI)